Introducing the newest breakthrough in microbiome technology – Celltermi NX Plus & HS! These probiotic-derived EV synergy sets are crafted with patented heritage ingredients that are redefining the next chapter of beauty science. The difference isn’t just what’s in the serum—it’s the science behind it. Developed by a leading biomaterial company with over 60 years of advancing medical innovation through research and manufacturing, Celltermi NX Plus & HS bring something increasingly rare to the regenerative aesthetics space: a foundation built on science and trust. These advanced topical serum kits help aesthetic professionals move beyond the hype and toward solutions they can confidently offer their patients.
CELLTERMI HS
Representing a next-generation approach to microenvironment support, Celltermi HS is a topical platform that integrates patented ingredients with advanced formulation science. The future of hair aesthetics requires more than a trendy story.
CELLTERMI NX PLUS
Rather than focusing on a single ingredient category, Celltermi NX Plus was developed around the broader biological environment of the skin. Designed for aesthetic professionals seeking more than conventional topical exosomes. Celltermi NX Plus reflects a foundation built on science-first expertise.
FOUNDATION BUILT ON EXPERIENCE
Crafted with patented heritage ingredients, Celltermi NX Plus & HS are designed by CHA Meditech who specialize in the development of cosmetics, biomaterials and medical devices. CHA Meditech, a subsidiary of the globally renowned CHA Bio Group, is a leading biomedical company specializing in the development and manufacturing of high-quality medical devices and aesthetic solutions. Its diverse portfolio includes premium hyaluronic acid fillers exported to over 30 countries worldwide. With over 60 years of innovation, CHA is redefining the next chapter in beauty science through TRANSDIFFERENTIATION.
CHA Meditech leverages the unique scientific foundation of CHA Bio Group, a pioneer in healthcare and regenerative medicine with over 65 years of experience. Based on the world’s largest cell library—including stem cells and immune cells—CHA Bio Group has secured full lifecycle capabilities in cell therapy, spanning from treatment development to Cell and Gene Therapy Contract Development and Manufacturing Organization (CGT CDMO) services. The group also operates Asia-Pacific’s largest medical network, with 96 medical institutions across 7 countries, including South Korea, the USA, Australia, Singapore, and Japan. Furthermore, integrating its proprietary technologies such as exosomes and stem cell conditioned media, the group is expanding its business lifecycle across life care, ranging from consumer-centered businesses like pharmaceuticals, health functional foods, beauty, and medical devices to digital healthcare.
